Startseite A new quality control model using performance goals based on biological variation in External Quality Assurance Schemes
Artikel
Lizenziert
Nicht lizenziert Erfordert eine Authentifizierung

A new quality control model using performance goals based on biological variation in External Quality Assurance Schemes

  • Ashraf Mina
Veröffentlicht/Copyright: 21. September 2011
Veröffentlichen auch Sie bei De Gruyter Brill

Abstract

A new quality control model using performance goals based on biological variation in External Quality Assurance Schemes (EQAS) is described. The proposed model aims to use assay (analytical) CVA, bias and total error available from participation in EQAS to describe assay performance using minimum, desirable and optimum quality specifications based on biological variation. The model provides further analysis of EQAS data and should be useful in better management of laboratory quality control, as it provides further information that can facilitate trouble-shooting. Additionally, it can help in evaluating the performance of current and proposed new laboratory methods by applying a unifying system if different EQAS are used to cover a range of analytes.


Corresponding author: Ashraf Mina, Department of Endocrinology, Institute of Clinical Pathology and Medical Research, Westmead Hospital, Westmead, New South Wales 2145, Australia Phone: +61-2-9845-7197, Fax: +61-2-9891-6908,

References

1. International Standard Organisation. Accuracy (trueness and precision) of measurement methods and results – Part 1. General principles and definitions. Geneva: ISO, 1994 (ISO/DIS 5725.http://www.iso.org/iso/en/Catalogue-DetailPage.CatalogueDetail?CSNUMBER=11833&scopelist=).Suche in Google Scholar

2. Fraser CG, Kallner A, Kenny D, Hyltoft Peterson P, editors. Strategies to set global analytical quality specifications in laboratory medicine. Scand J Clin Lab Invest 1999; 59:477–8.10.1080/00365519950185184Suche in Google Scholar

3. Cornbleet PJ, Gochman N. Incorrect least-squares regression coefficients in method-comparison analysis. Clin Chem 1979; 25:432–8.10.1093/clinchem/25.3.432Suche in Google Scholar

4. Linnet K. Necessary sample size for method comparison studies based on regression analysis. Clin Chem 1999; 45:882–94.10.1093/clinchem/45.6.882Suche in Google Scholar

5. Linnet K. Performance of Deming regression analysis in case of misspecified analytical error ratio in method comparison studies. Clin Chem 1998; 44:1024–31.10.1093/clinchem/44.5.1024Suche in Google Scholar

6. Linnet K. Evaluation of regression procedures for methods comparison studies. Clin Chem 1993; 39:424–32.10.1093/clinchem/39.3.424Suche in Google Scholar

7. Linnet K. Estimation of the linear relationship between measurements of two methods with proportional errors. Stat Med 1990; 9:1463–73.10.1002/sim.4780091210Suche in Google Scholar PubMed

8. Ridgeway M. Quality control technologies – participants' manual, version 1.1 Charleston, NSW, Australia: QC Technologies. 5.1–5.5 (http://www.qctpl.com.au).Suche in Google Scholar

9. Fraser CG, Harris EK. Generation and application of data on biological variation in clinical chemistry. Crit Rev Clin Lab Sci 1989; 27:409–37.10.3109/10408368909106595Suche in Google Scholar PubMed

10. Ricós C, Alvarez V, Cava F, Garcia-Lario JV, Hernandez A, Jimenez CV, et al. Current databases on biological variation: pros, cons and progress. Scand J Clin Lab Invest 1999; 59:491–500.10.1080/00365519950185229Suche in Google Scholar PubMed

11. The Royal College of Pathologists of Australasia –Australian Association of Clinical Biochemists (RCPA-AACB) External Quality Assurance Program (http://www.repaqap.com.au).Suche in Google Scholar

12. Fraser CG. Biological variation: from principles to practice. Washington, DC: AACC Press 2001:139.Suche in Google Scholar

13. Westgard website. www.westgard.com (biological variation).Suche in Google Scholar

Received: 2005-8-28
Accepted: 2005-10-5
Published Online: 2011-9-21
Published in Print: 2006-1-1

©2006 by Walter de Gruyter Berlin New York

Artikel in diesem Heft

  1. Where does the evidence come from?
  2. NASBA: a novel approach to assess hormonal receptors and ERBB2 status in breast cancer
  3. Plasma cell-free DNA as an indicator of severity of injury in burn patients
  4. Bivariate statistical approach to evaluate laboratory performance by analysis of standard curves in an External Quality Assurance program for quantitative assays based on real-time PCR with Taq-Man™ probes
  5. Erythrocyte membrane acetylcholinesterase activity in subjects with MTHFR 677C→T genotype
  6. Plasma levels of tumor M2-pyruvate kinase should not be used as a tumor marker for hematological malignancies and solid tumors
  7. APO A-V–1131T→C polymorphism frequency and its association with morbidity in a Brazilian elderly population
  8. Association study between fibronectin and coronary heart disease
  9. Serum calcium and phosphorus associate with the occurrence and severity of angiographically documented coronary heart disease, possibly through correlation with atherogenic (apo)lipoproteins
  10. Urinary calcium excretion in severe preeclampsia and eclampsia
  11. In vitro re-mineralization of demineralized bone matrix in human serum
  12. Measurement of serum amyloid A1 (SAA1), a major isotype of acute phase SAA
  13. Disturbed lipoprotein composition in non-dialyzed, hemodialysis, continuous ambulatory peritoneal dialysis and post-transplant patients with chronic renal failure
  14. Measurement of serum testosterone using high-performance liquid chromatography/tandem mass spectrometry
  15. Quantitative bacterial micro-assay for rapid detection of serum phenylalanine on dry blood-spots: application in phenylketonuria screening
  16. N-Terminal pro-brain natriuretic peptide: normal ranges in the pediatric population including method comparison and interlaboratory variability
  17. A new quality control model using performance goals based on biological variation in External Quality Assurance Schemes
  18. Improvement in glycemic control over 11 years in patients monitored for diabetes in one county
  19. The clinical usefulness of glucose tolerance testing in gestational diabetes to predict early postpartum diabetes mellitus
  20. Analytical performance of a new two-step ADVIA Centaur® estradiol immunoassay during ovarian stimulation
  21. EC4 European Syllabus for Post-Graduate Training in Clinical Chemistry and Laboratory Medicine: version 3 – 2005
  22. POX-Act assay and d-ROMs test – what are the facts?
  23. External quality control of urinary methyl malonic acid quantification – announcement of a pilot study
Heruntergeladen am 7.11.2025 von https://www.degruyterbrill.com/document/doi/10.1515/CCLM.2006.017/html
Button zum nach oben scrollen